205 related articles for article (PubMed ID: 25208121)
1. Immunoscintigraphy and radioimmunotherapy in Cuba: experiences with labeled monoclonal antibodies for cancer diagnosis and treatment (1993-2013).
Peña Y; Perera A; Batista JF
MEDICC Rev; 2014; 16(3-4):55-60. PubMed ID: 25208121
[TBL] [Abstract][Full Text] [Related]
2. [Immunoscintigraphy and radioimmunotherapy of cancer using monoclonal antibodies].
Oriuchi N
Gan To Kagaku Ryoho; 1999 May; 26(6):762-7. PubMed ID: 10410144
[TBL] [Abstract][Full Text] [Related]
3. Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors.
Behr TM; Sharkey RM; Juweid MI; Dunn RM; Ying Z; Zhang CH; Siegel JA; Gold DV; Goldenberg DM
Cancer Res; 1996 Apr; 56(8):1805-16. PubMed ID: 8620497
[TBL] [Abstract][Full Text] [Related]
4. Pretargeting strategies for radio-immunoguided tumour localisation and therapy.
Stoldt HS; Aftab F; Chinol M; Paganelli G; Luca F; Testori A; Geraghty JG
Eur J Cancer; 1997 Feb; 33(2):186-92. PubMed ID: 9135486
[TBL] [Abstract][Full Text] [Related]
5. [Radioimmunotargeting: diagnosis and therapeutic use].
Vuillez JP
Bull Cancer; 2000 Nov; 87(11):813-27. PubMed ID: 11125290
[TBL] [Abstract][Full Text] [Related]
6. Radiolabeling and biological evaluation of DOTA-Ph-Al derivative conjugated to anti-EGFR antibody ior egf/r3 for targeted tumor imaging and therapy.
Pnwar P; Iznaga-Escobar N; Mishra P; Srivastava V; Sharma RK; Chandra R; Mishra AK
Cancer Biol Ther; 2005 Aug; 4(8):854-60. PubMed ID: 16082184
[TBL] [Abstract][Full Text] [Related]
7. Is there a future role for immunoscintigraphy in the diagnosis of colorectal carcinoma?
Artiko VM; Sobić-Saranović DP; Krivokapić ZV; Petrović MN; Obradović VB
Neoplasma; 2009; 56(1):1-8. PubMed ID: 19152238
[TBL] [Abstract][Full Text] [Related]
8. Radioimmunodetection and radioimmunotherapy of malignant melanoma. A review.
Liewendahl K; Pyrhönen S
Acta Oncol; 1993; 32(7-8):717-21. PubMed ID: 8305217
[TBL] [Abstract][Full Text] [Related]
9. Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor.
Crombet T; Torres O; Neninger E; Catalá M; Rodríguez N; Ramos M; Fernández E; Iznaga N; Pérez R; Lage A
Cancer Biother Radiopharm; 2001 Feb; 16(1):93-102. PubMed ID: 11279803
[TBL] [Abstract][Full Text] [Related]
10. [Immunotargeting of tumors: state of the art and prospects in 2000].
Pèlegrin A; Xavier F; Barbet J; Bartholeyns J; Baty D; Buchegger F; Chatal JF; Dufief F; Gurreau D; Gruaz-Guyon A; Lamotte D; Leserman L; Mach JP; Robert B; Saccavini JC; Teillaud JL; Teulon I
Bull Cancer; 2000 Nov; 87(11):777-91. PubMed ID: 11125287
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic applications and therapeutic approaches with different preparations of anti-CEA antibodies.
Bischof Delaloye A; Delaloye B
Int J Biol Markers; 1992; 7(3):193-7. PubMed ID: 1431345
[TBL] [Abstract][Full Text] [Related]
12. A novel platform for radioimmunotherapy: extracorporeal depletion of biotinylated and 90Y-labeled rituximab in patients with refractory B-cell lymphoma.
Lindén O; Kurkus J; Garkavij M; Cavallin-Ståhl E; Ljungberg M; Nilsson R; Ohlsson T; Sandberg B; Strand SE; Tennvall J
Cancer Biother Radiopharm; 2005 Aug; 20(4):457-66. PubMed ID: 16114994
[TBL] [Abstract][Full Text] [Related]
13. Radioimmunoimaging and radioimmunotherapy: will these be routine procedures?
Bischof Delaloye A
Semin Nucl Med; 2000 Jul; 30(3):186-94. PubMed ID: 10928382
[TBL] [Abstract][Full Text] [Related]
14. Tumor pretargeting for radioimmunodetection and radioimmunotherapy.
Zhu H; Jain RK; Baxter LT
J Nucl Med; 1998 Jan; 39(1):65-76. PubMed ID: 9443740
[TBL] [Abstract][Full Text] [Related]
15. Freeze-dried formulation for direct 99mTc-labeling ior-egf/r3 MAb: additives, biodistribution, and stability.
Morales AA; Núñez-Gandolff G; Pérez NP; Véliz BC; Caballero-Torres I; Ducongé J; Fernández E; Crespo FZ; Veloso A; Iznaga-Escobar N
Nucl Med Biol; 1999 Aug; 26(6):717-23. PubMed ID: 10587113
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibodies: old and new trends in breast cancer imaging and therapeutic approach.
Stipsanelli E; Valsamaki P
Hell J Nucl Med; 2005; 8(2):103-8. PubMed ID: 16142251
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic efficacy and safety of 99mtc-labeled monoclonal antibody ior c5 in patients with colorectal and anal carcinomas: final report clinical trial phase I/II.
Ramos-Suzarte M; Pintado AP; Mesa NR; Oliva JP; Iznaga-Escobar N; Aroche LT; Pimentel G; González J; Cordero M; Rodríguezi OT; Crombet RT; Pérez RR
Cancer Biol Ther; 2007 Jan; 6(1):22-9. PubMed ID: 17224642
[TBL] [Abstract][Full Text] [Related]
18. Radioimmunodetection and radioimmunotherapy of head and neck cancer.
Börjesson PK; Postema EJ; de Bree R; Roos JC; Leemans CR; Kairemo KJ; van Dongen GA
Oral Oncol; 2004 Sep; 40(8):761-72. PubMed ID: 15288829
[TBL] [Abstract][Full Text] [Related]
19. 99mTc-labeled antihuman epidermal growth factor receptor antibody in patients with tumors of epithelial origin: Part III. Clinical trials safety and diagnostic efficacy.
Ramos-Suzarte M; Rodríguez N; Oliva JP; Iznaga-Escobar N; Perera A; Morales A; Gonzalez N; Cordero M; Torres L; Pimentel G; Borrón M; González J; Torres O; Rodríguez T; Pérez R
J Nucl Med; 1999 May; 40(5):768-75. PubMed ID: 10319748
[TBL] [Abstract][Full Text] [Related]
20. [Monoclonal antibodies. An approach to diagnosis and treatment of micrometastases].
Bier H
HNO; 1994 May; 42(5):255-6. PubMed ID: 8050912
[No Abstract] [Full Text] [Related]
[Next] [New Search]
